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ttp://dx.doi.org/10.1016/j.ajpath.2013.04.030AMP-activated protein kinase (AMPK) signaling is reported to protect neurons under pathologic condi-
tions; however, its effect on oligodendrocytes (OLs) remains to be elucidated. We investigated whether
AMPK signaling protects OLs to restore central nervous system (CNS) functions in an experimental
autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis. Increased inﬂammation and
demyelination in the CNS and peripheral immune responses were consistent with the observed clinical
impairments in EAE animals, which were attenuated by treatment with metformin compared with vehicle.
In addition, expressions of neurotrophic factors and of signatory genes of OL lineages were increased in
the CNS of metformin-treated EAE animals. Likewise, metformin attenuated inﬂammatory response and
enhanced expressions of neurotrophic factors, thereby protecting OLs via AMPK activation in mixed glial
cultures stimulated with lipopolysaccharide/interferon g in vitro, as evidenced by analysis of the
expression of signatory genes of O1þ/MBPþ OLs and their cellular populations. Metformin also attenuated
oxidative stress and malondialdehyde-containing protein levels, with corresponding induction of anti-
oxidative defenses in OLs exposed to cytokines via AMPK activation. These effects of metformin were
evident in the CNS of EAE animals. These data provide evidence that AMPK signaling is crucial to protect
OLs and, thus, CNS functions in EAE animals. We conclude that AMPK activators, including metformin,
have the potential to limit neurologic deﬁcits in multiple sclerosis and related neurodegenerative
disorders. (Am J Pathol 2013, 183: 526e541; http://dx.doi.org/10.1016/j.ajpath.2013.04.030)Supported by NIH grants VA-1BX001072, VA-BX001999, NS-22576,
NS-37766, and C06-RR018823.
A.S.P. and M.K.P. contributed equally to this study.The critical role of oligodendrocytes (OLs) in producing and
maintaining the myelin sheath around axons that supports
rapid salutatory conduction in central nervous system (CNS)
neurons is well established.1 In addition, OLs are reported to
provide trophic factors and metabolic support for neurons.2e4
The CNS has the inherent capacity to generate myelin-
forming OLs after episodes of demyelination under various
pathologic conditions.5 Persistent demyelination is one of the
pathologic hallmarks of multiple sclerosis (MS) and spinal
cord (SC) trauma, which is responsible for neurologic deﬁcits
in affected individuals.6,7 Therefore, a major question in
neurobiology today is how to protect OLs in CNS demye-
linating diseases, includingMS, to limit neurologic deﬁcits in
affected individuals.stigative Pathology.
.Pro- and anti-inﬂammatory cytokines are known to play
critical roles in the survival and generation of myelin-forming
OLs that are lost after a demyelination attack.8,9 OLs are
required for the induction of remyelination to restore the
structural integrity of the axon-myelin unit and axonal
conduction properties in the MS brain.9 Proinﬂammatory
cytokine signaling is reported to induce OL death and is
antagonized by anti-inﬂammatory cytokine signaling mech-
anisms.10e13 In MS brain lesions, spontaneous remyelination
follows the demyelination attack in acute lesions.7 In
AMPK Signaling and OLs Survival in EAEcontrast, remyelination fails in chronic lesions, irrespective
of the presence of OL progenitor cells (OPCs).14 OPCs
transplanted into demyelinated SC lesions, however, are re-
ported to enhance remyelination in adult rats.1 Consistently,
we earlier documented that lovastatin enhances the differ-
entiation of OPCs into myelin-forming OLs that eventually
enhance remyelination in experimental autoimmune en-
cephalomyelitis (EAE), a murine model of MS.15,16 In light
of this information, we assessed whether a pharmacologic
agent that can inﬂuence OL survival holds promise to restore
CNS integrity and functions in MS.
Accumulating evidence suggests that AMP-activated
protein kinase (AMPK)emediated restoration of the CNS
energy balance is critical to protect the brain under pathologic
conditions.17,18 We earlier documented that AMPK activa-
tors, ie, 5-amino-4-imidazole carboxamide riboside (AICAR)
and metformin, attenuate clinical impairments in EAE
animals.19,20 The protective effects of these AMPK activators
were ascribed to their immunomodulatory activities and the
restoration of blood-brain barrier integrity in EAE ani-
mals.19e21 AMPK activity was reduced in the brain at the
onset and peak of EAE disease.22 Consistently, we earlier
documented that the genetic ablation of AMPK causes severe
clinical impairments in EAE animals.23 In addition, we
documented that AICAR inhibits the expressions of inﬂam-
matory mediators in astrocytes, microglia, and peritoneal
macrophages that are known to play critical roles in EAE/MS
pathogenesis.24 Recently, AMPK signaling was reported
to interfere with interferon g (IFN-g)emediated activation
of astrocytes and microglia22 as well as induction of the
inﬂammatory response in liver cells.25,26 These studies pro-
vide evidence that CNS bioenergetics and inﬂammation are
linked, thus understanding of their regulatory mechanisms has
the scope to identify new therapeutic interventions for MS.
Recently, AMPK signalingwas reported to protect neurons
under pathologic conditions.27,28 In addition, we earlier
documented that AMPK activity was reduced in OLs exposed
to psychosine, a galactosylsphingosine lipid that accumulates
in the Krabbe brain.29 Based on this knowledge, we investi-
gatedwhetherAMPKsignaling can protectOLs in theCNSof
EAE animals. By using in vitro and in vivo approaches, we
demonstrated that AMPK signaling inﬂuences OL survival
and, thereby, restores CNS integrity and functions in EAE
animals treated with metformin (ﬁrst-line drug of choice for
type 2 diabetes mellitus).
Materials and Methods
Chemicals and Reagents
Unless otherwise stated, all the chemicals were purchased
from Sigma-Aldrich (St. Louis, MO). Dulbecco’s modiﬁed
Eagle’s medium (containing 4.5 g/L of glucose), fetal bovine
serum, poly-D-lysine, rat IgG, and rabbit polyclonal IgG
(control primary antibodies) and secondary antibodies, ie,
Alexa Fluor conjugated with anti-rabbit IgG or anti-mouseThe American Journal of Pathology - ajp.amjpathol.orgIgG, were purchased from Life Technologies (Grand Island,
NY). Recombinant platelet-derived growth factor (PDGF)-
aa, basic ﬁbroblast growth factor-2, ciliary neurotrophic
factor (CNTF), tumor necrosis factor a (TNF-a) and IL-1b
proteins were purchased from R&D Systems (Minneapolis,
MN). Antiemyelin basic protein (MBP) antibodies were
purchased from Santa Cruz Biotechnology (Dallas, TX).
Anti-A2B5 MicroBeads and MS columns were purchased
from MACS, Miltenyi Biotec Inc. (Auburn, CA). Anti-O1,
anti-A2B5, antieTNF-a, antienitric oxide synthase-II (NOS-
II), antieheme oxygenase-1, antiemanganese superoxide
dismutase 2 (SOD2), antiephospho-AMPKa, and anti-
AMPKa1 antibodieswere purchased fromMillipore (Billerica,
MA). Rabbit anti-malondialdehyde (MDA) polyclonal anti-
bodies were purchased from Cell Biolabs (San Diego, CA).
Electrochemiluminescence-detecting reagents and nitrocellu-
lose membranes were purchased from GE Healthcare Biosci-
ences (Pittsburg, PA).
Animals
Adult female Lewis rats weighing 250 to 300 g or pregnant
Sprague Dawley rats at embryonic gestation day 18 were
purchased from Charles River Laboratories (Wilmington,
MA) and were housed in the animal care facility at the
Medical University of South Carolina (Charleston, SC)
throughout the experiment and were provided with food and
water ad libitum. All the animal experiments were conducted
in accordance with accepted standards of humane care, as
outlined in the ethical guidelines and approved by theMedical
University of South Carolina’s Animal Ethics Committee.
EAE Induction and Evaluation
The procedures used for induction of EAE are as described in
previous publications with slight modiﬁcations.15,30 In brief,
the rats received an s.c. injection of 25mg of guinea pigMBP in
0.1 mL of PBS emulsiﬁed with an equal volume of complete
Freund’s adjuvent supplemented with 2 mg/mL of mycobac-
terium tuberculosis H37Ra (Difco, Detroit, MI) in the hind
limb foot pads on days 0 and 7. Immediately and again 24 hours
later, the rats received 200 ng of pertussis toxin i.p. in 0.1mL of
PBS. Pertussis toxin was used as per the standardized protocol
reported by us and other investigators for the induction of EAE.
Similarly, healthy control group rats received an s.c. injection
of PBS and complete Freund’s adjuvant emulsion in the hind
limb foot pads on days 0 and 7. The rats were examined for
clinical scores by an experimentally blinded investigator
(A.K.S.) daily. Clinical scores were assessed using a scale from
0 to 5: 0, no clinical disease; 1.0, piloerection; 2.0, loss in tail
tonicity; 3.0, hind leg paralysis; 4.0, paraplegia, and 5.0,
moribund or dead. At several times during the study, rats were
weighed. The clinical data from rats with a clinical score >4.0
were not included in the statistical analysis. At the conclusion
of the study, the rats were euthanized, perfusion was per-
formed, and the lumbar SC was removed, snap frozen with527
Paintlia et alliquid nitrogen, and stored at 70C until use. Alternatively,
the SC of each ratwas cut into four small pieces andﬁxed in 4%
paraformaldehyde for histopathologic analysis.
Drug Treatments
Metformin, 150 mg/mL, was suspended in PBS and admin-
istered by gavages every day in a 200-mL volume. Treatment
was started in rats with established EAE (day 11 or 12 after
immunization) and continued until the lessening of paralytic
symptoms (day 22 after immunization; recovery). Control
EAE rats without drug treatment received PBS once daily.
Likewise, healthy control rats received vehicle or metformin
once daily.
Cultures and Treatments of OLs
Mixed glial cell cultures were generated from the brains of
P1eP2 pups obtained from Sprague Dawley mothers as
described earlier.31 Brieﬂy, dissociated cortices in Dulbec-
co’s modiﬁed Eagle’s medium containing 10% fetal bovine
serum and 4 mmol/L L-glutamine were cultured on ﬂasks
coated with 50 mg/mL of poly-D-lysine before use. After 10
days, the cells were used directly for studies or the ﬂasks were
shaken (250 rpm) for 2 hours to remove microglia. The ﬂasks
were shaken for another 8 hours, and OPCs were dislodged
from the astrocyte layer. Pure OPC cultures >99.9% were
generated by using anti-A2B5 MicroBeads and passing
through MS columns (MACS, Miltenyi Biotec). Puriﬁed
OPCs (2000 cells/cm2) were plated on poly-D-lysineecoated
culture dishes or glass coverslips in serum-free modiﬁed
Bottenstein-Satoebased medium as described earlier.32 After
24 hours, Bottenstein-Satoebased medium supplemented
with 10 ng/mL of CNTF was replaced, which showed the
transformation of OPCs into OLs (O1þ) at 48 hours of
incubation. These OLs were grown in 24-well cell culture
plates or 100 cm2 culture dishes and were exposed to 10 ng/
mL of TNF-a and 20 ng/mL of IL-1b, simultaneously, in the
presence or absence of metformin. OPC-enriched (20%)
mixed glial cultures were plated in 6-well cell culture plates
(2000 cells/cm2) in Dulbecco’s modiﬁed Eagle’s medium
containing 5% fetal bovine serum and 25 mg/mL of genta-
micin (Nunc, Roskilde, Denmark) and were incubated at
37C in a humidiﬁed atmosphere of 95% air and 5% CO2.
Cell cultures with 70% to 80% conﬂuence were used to treat
with 100 ng/mL of lipopolysaccharide (LPS) and 50 ng/mL of
IFN-g in the presence or absence of metformin or pharma-
cologic agents. Concentrations of the pharmacologic agents
used in the study showed no cell toxicity as revealed by trypan
blue exclusion and lactate dehydrogenase release assays.
Endogenous ROS Measurement
The reactive oxygen species (ROS) was determined using
amicroplate reader. Cells were plated in 24-well culture plates
and were treated with cytokines in the presence or absence of528metformin (Cultures and Treatment of OLs). For positive
control, before performing the assay, cells were treated with
0.3%H2O2 suspended in culturemedium and incubated for 30
minutes at 37C. After 24 hours of incubation, the cells were
washedwith PBS (3) andwere incubatedwith 5mmol/L cell-
permeable ﬂuorescent dye 5-(and-6)-chloromethyl-20,70-
dichlorodihydroﬂuorescein diacetate (CM-DCFDA; Life
Technologies) in serum-free medium as described previ-
ously.33After incubating for 30minutes, the cellswerewashed
with PBS and lyzed in cell lysis buffer (0.1N of NaOH in 50%
methanol). From eachwell, 200mL of solutionwas transferred
to a 96-well black microplate. Changes in ﬂuorescence were
determined at excitation/emission Z 485/530 nm using
a SoftMax Pro spectroﬂuorometer (Molecular Devices, Sun-
nyvale, CA).
Measurement of Mitochondrial Membrane Potential
Changes in mitochondrial membrane potential were mea-
sured in cells using JC-1 (5,50,6,60-tetrachloro-1,10,3,30-
tetraethylbenzimidazolylcarbocyanine iodide) dye. Cells
were incubated with 1 mmol/L JC-1 dye for 15 minutes at
37C. Then cells were rinsed in PBS (2) and examined by
ﬂuorescence microscopy (Olympus BX60) and photographed
using the attachedOlympus digital camera (Optronics, Goleta,
CA). Oxidative stress usually causes the disruption of mito-
chondrial membrane potential. JC-1 dye indicates mitochon-
dria depolarization by a change from red to greenﬂuorescence.
Immunocytochemical and Histopathologic Studies
For single labeling, a standardmethodwas used.Brieﬂy, slides
were blocked by using an Image-iT ﬁxation and per-
meabilization kit (Life Technologies) andwere incubatedwith
appropriately diluted primary antibody (dilution 1:100) at 4C
overnight followed by washing and further incubation with
secondary antibodies, Alexa Fluor 488econjugated goat anti-
rabbit IgG antibodies (dilution 1:500) for 1 hour. For double
labeling, slides were incubated simultaneously or separately
with both types of primary antibodies after blocking with
a serum-PBS solution at 4C overnight as described for single
labeling. Secondary antibodies Alexa Fluor 488econjugated
goat anti-rabbit IgG (CNTF) or Alexa Fluor 594econjugated
rabbit anti-mouse IgG [glial ﬁbrillary acidic protein (GFAP)]
antibodies were used. Slides were also incubated with Alexa
Fluoreconjugated IgG antibodies without primary antibody
as negative controls and an appropriate mouse IgG or rabbit
polyclonal IgG as isotype controls. After thorough washings,
slides were mounted using Fluoromount-G (Electron Micro-
scopySciences,Hatﬁeld, PA) containingHoechst. Slideswere
examined using a ﬂuorescence microscope (Olympus BX60),
and images were captured at magniﬁcations 400 using an
Olympus digital camera (Optronics) using a dual-bandpass
ﬁlter. The contrast and brightness of images were processed
using Adobe Photoshop CS5 software (Adobe Systems Inc.,
San Jose, CA).ajp.amjpathol.org - The American Journal of Pathology
Table 1 Primers Used for Quantitative Real-Time PCR Analysis
Gene
name Primer sequence
b-actin Forward: 50-AGCTGTGCTATGTTGCCCTAGACT-30
Reverse: 50-ACCGCTCATTGCCGATAGTGATGA-30
TNF-a Forward: 50-CTTCTGTCTACTGAACTTCGGGGT-30
Reverse: 50-TGGAACTGATGAGAGGGAGCC-30
NOS-II Forward: 50-GGAAGAGGAACAACTACTGCTGGT-30
Reverse: 50-GAACTGAGGGTACATGCTGGAGC-30
IFN-g Forward: 50-TTTGAGGTCAACAACCCACAGGTC-30
Reverse: 50-TTTCCGCTTCCTGAGGCTGGATT-30
IL-17A Forward: 50-TCTGAGCCAGCCAAGAAGAAGTGT-30
Reverse: 50-TTCCAACCCAAACATAGGCAC-30
ROR-gt Forward: 50-AGGCCATTCAGTATGTGGTGGAGT-30
Reverse: 50-TGTGTGGTTGTTGGCATTGTAGGC-30
IL-4 Forward: 50-GGTATCCACGGATGTAACGACAGC-30
Reverse: 50-CCGTGGTGTTCCTTGTTGCCGTAA-30
IL-10 Forward: 50-CTGTCATCGATTTCTCCCTGTGAG-30
Reverse: 50-TGAGTGTCACGTAGGCTTTCATGC-30
FoxP3 Forward: 50-AGAGTTTCTCAAGCACTGCCAAGC-30
Reverse: 50-TGCATAGCTCCCAGCTTCTCCTTT-30
CD4 Forward: 50-AGGTCTCCCTTCAGTTTGCTGGTT-30
Reverse: 50-TCACCACCAGGTTCACTTCCTGAT-30
CD8 Forward: 50-AAAGCAAGACCTGGACCAACGAGA-30
Reverse: 50-TAACGTGCCTGACCATTCACAGGA-30
CD11b Forward: 50- GGGAGATGTGAATGGAGACAAA-30
Reverse: 50- GTACTGATGCTGGCTACTGATG-30
CCL3 Forward: 50-TCCTATGGACGGCAAATTCCACGA-30
Reverse: 50-AGATCTGCCGGTTTCTCTTGGTCA-30
CCL5 Forward: 50-TGTGTGCCAACCCAGAGAAGAAGT-30
Reverse: 50-TAGCATCTATGCCCTCCCAGGAAT-30
CXCL10 Forward: 50-TGCAAGTCTATCCTGTCCGCATGT-30
Reverse: 50-CCTTCTTTGGCTCACCGCTTTCAA-30
SOD2 Forward: 50-AAACTGACAGCTGTGTCTGTGGGA-30
Reverse: 50-TTGCAGTGGGTCCTGATTAGAGCA-30
PDGF-aR Forward: 50-CAGACATTGACCCTGTTCCAGAGG-30
Reverse: 50-GAATCTATGCCAATATCATCCATC-30
Olig2 Forward: 50-TGCGCAAGCTCTCCAAGATCG-30
Reverse: 50-TCTCGCTCACCAGTCTCTTCATCT-30
MBP Forward: 50-CTCTGGCAAGGACTCACACAC-30
Reverse: 50-TCTGCTGAGGGACAGGCCTCTC-30
SOX10 Forward: 50-TCTACACGGCCATCTCTGACC-30
Reverse: 50-GTCGTATATACTGGCTGTTCCCAGTG-30
PDGF Forward: 50-AGGATGCCTTGGAGACAAACCTGA-30
Reverse: 50-ACTGCGGGAATGGCTTCCTCAATA-30
CNTF Forward: 50-CTTCAAGAGCTCTCACAGTG-30
Reverse: 50-TGCTTATCTTTGGCCCCATAAT-30
AMPK Signaling and OLs Survival in EAEFixed SC sections of 5 mmwere stained with Luxol fast blue
and H&E (Sigma-Aldrich) and were examined using light
microscopy (Olympus BX60). Images were acquired using an
Olympus digital camera (Optronics). The region of SC depict-
ing >10 nuclei was considered as lesion. The meanings, gray
matter, andwhite matter of the sections were scored in a blinded
manner based on the presence or absence of inﬁltrating cells in
each region of the SC. Histopathology scores were recorded
as the number of lesions in the SC of each group of rats
that showed a readily identiﬁable inﬂammatory cell inﬁltrate.
Similarly, demyelination in the white matter of the SC was
examined and scored. The demyelination degree was scored as
grade 0, no disease; grade 1, foci of demyelination/axonal loss
that is superﬁcial and involves <25% of the lateral columns;
grade 2, deep foci that involve >25% of the lateral columns;
and grade 3, diffuse and widespread demyelination and axonal
loss. Histologic data are from ﬁve rats per group, where three to
four sections per rat were examined for the presence of lesions.
RNA Preparation, cDNA Synthesis, and Real-Time PCR
Analysis
Cells or tissues were carefully processed for RNA isolation
using TRIzol reagent (Invitrogen, Carlsbad, CA) followed by
cDNA synthesis and real-time PCR analysis using a Bio-Rad
CFX96 system (Bio-Rad Laboratories, Hercules, CA). The
primer sets used in the study (Table 1) were designed using
PrimerQuest and were synthesized by Integrated DNA Tech-
nologies (Coralville, IA). iQ SYBR Green supermix was
purchased from Bio-Rad Laboratories. Thermal cycling
conditions were as follows: activation of iTaq DNA poly-
merase (Bio-Rad Laboratories) at 95C for 10 minutes fol-
lowed by40 cycles of ampliﬁcation at 95C for 30 seconds and
59C to 60C for 30 seconds. The speciﬁcity and detection
methods for data analysis are as described earlier.31 In brief,
real-time PCR speciﬁcity for each analysis was determined by
melting curve analysis of the ampliﬁed product. The level of
target gene transcriptswas calculated relative to the expression
of reference gene, b-actin, in each sample. The detection of
threshold was set above the mean baseline ﬂuorescence
determined by the ﬁrst 20 cycles. A standard curve for each
template was generated with a serial dilution of the template
(cDNA). Likewise, cytokine and chemokine expressions were
measured by using cytokine and chemokine PCR arrays
(PARN-150ZD-2; Qiagen Inc., Valencia, CA) with cDNA of
each sample, using real-time PCR at conditions described
in the product manual. Data were analyzed using website-
based RT2 Proﬁler PCR data analysis software version 3.5
(SABiosciences, a QIAGEN company, Valencia, CA).
Enzyme Assays and ELISA Methods
Extracts of tissues or cells were collected by homogeniza-
tion in PBS and centrifugation at 14,000 rpm for 15 minutes
at 4C. Protein, 50 to 100 mg per sample, in extract was used
for AMPK activity measurement using AMPK KinEASE FPThe American Journal of Pathology - ajp.amjpathol.orgﬂuorescein green assay kit (32-007; Millipore) as instructed
in the product manual. Data are presented as percentage of
controls. Likewise, SOD activity in the extracts was mea-
sured using SOD determination kits (19160-1KT-F; Sigma-
Aldrich) as instructed in the product manual. Data are
presented as percentage of inhibition that reﬂects SOD
activity. CNTF levels in the culture supernatants or tissue
extracts were measured by using an enzyme-linked immu-
nosorbent assay (ELISA) kit as per instructions in the product
manual (R&D Systems). Anti-MBPespeciﬁc IgG isotypes
were detected in serum samples by solid-phase ELISA as529
Figure 1 Metformin limits clinical impairments
with reduction of inﬂammation and demyelination
in the SCs of EAE rats. A: EAE was induced with 25
mg per rat guinea pig MBP in female Lewis rats,
and 150 mg/kg of metformin or vehicle treatments
were started orally by gavages in rats with estab-
lished EAE and healthy controls (CON). B:
Composite means  SEM of the clinical scores in
rats (nZ 9 per group) evaluated in three separate
experiments. C: Composite means  SEM of three
to four samples per group analyzed for AMPK
activity in the SCs of EAE rats. D: Representative
images of the longitudinal and cross section of
lateral funiculi of the SCs of rats (nZ 6 per group)
stained with Luxol fast blue (LFB) plus H&E depict
cellular inﬁltration and demyelination. Asterisks
in D depict cellular inﬁltration and demyelination
in the white mater. Composite means  SEM of the
number of inﬂammatory lesions (E) and degree of
demyelination (F) in the SCs of EAE rats (nZ 6 per
group) on day 23 after immunization. Recovery
indicates lessening of clinical symptoms. **P <
0.01, ***P < 0.001.
Paintlia et aldescribed earlier,34 where Luminata Forte substrate (Milli-
pore) was used for horseradish peroxidase enzyme assay.
Detection of Nitrite Levels
Nitrite levels in the culture supernatants were measured by
using Griess reagent as described elsewhere.35
Western Blot Analysis
Total cell lysates were prepared in ice-cold lysis buffer
(radioimmunoprecipitation assay buffer) and were used for
Western blot analysis as described elsewhere.32 Autoradio-
graphs were scanned and the band intensity was quantiﬁed
by using ImageJ software (NIH, Bethesda, MD).
Detection of Cell Viability and Cell Death
Cell viability was determined by trypan blue exclusion
assay by mixing 10 mL of 0.4% trypan blue solution with 10
mL of cell suspension and reading the results using a TC10
automated cell counter (Bio-Rad Laboratories). Cell death
was analyzed by measuring lactate dehydrogenase enzyme530activity in the culture supernatants using a lactate dehy-
drogenase release assay kit (Roche Diagnostics Corp.,
Indianapolis, IN).
Statistical Analysis
Data are given as means  SEM and were analyzed by using
Student’s t-test for two-group comparisons or one-waymultiple-
range analysis of variance for multiple-column comparisons,
followed by a Bonferroni posttest. P values were determined
for three to four separate samples in each experiment using
GraphPad Prism software version 5.0 (GraphPad Software Inc.,
San Diego, CA). P < 0.05 was considered signiﬁcant.
Results
Metformin Attenuates Inﬂammation in the Peripheral
and CNS Compartments, Limiting Clinical Impairments
in EAE Animals
In the experiments described herein, we used metformin to
treat female Lewis rats with established EAE exhibitingajp.amjpathol.org - The American Journal of Pathology
Figure 2 Metformin enhances expression of the signatory genes of OL
lineage cells and of the neurotrophic factors in the SCs of EAE rats.
Induction of EAE in rats and treatment with metformin or vehicle were as
detailed in the legend to Figure 1. Composite means  SEM of three to four
samples per group analyzed in triplicate for levels of PDGF-aR (A), Olig2
(B), MBP (C), SOX10 (D), CNTF (E), and PDGF (F) mRNA transcripts in the SCs
of EAE rats on day 23 after immunization. CON, control. **P < 0.01,
***P < 0.001.
AMPK Signaling and OLs Survival in EAEclinical scores 3.0 (Figure 1A). The observed higher clin-
ical scores in EAE rats were reduced signiﬁcantly by treat-
ment with metformin compared with vehicle (Figure 1B).
This lessening of clinical disease in metformin-treated EAE
rats was accompanied by a reduction of cellular inﬁltration
and demyelination in their SCs (Figure 1, DeF). For
example, the mean  SD number of inﬂammatory lesions
was increased in the SCs of EAE rats treated with vehicle
(33.5  9.9) compared with controls and were reduced
signiﬁcantly (10.4  4.4; P < 0.01) by treatment with met-
formin (Figure 1E). In addition, metformin attenuated the
mean  SD degree of demyelination in the SCs of EAE rats
compared with vehicle treatment, ie, 1.0  0.7 versus 2.5 
0.67, respectively (Figure 1F). Note that the number of
inﬂammatory lesions and the degree of demyelination were
signiﬁcantly low in the SCs of EAE rats on the peak clinical
day compared with the lessening of symptoms (recovery
phase) (Figure 1, E and F). A recent study reported that
AMPK activity was reduced in the brain at the onset and peak
of EAE disease.22 Therefore, we next assessed the status of
AMPK activity in similarly treated EAE rats. As expected,
AMPK activity was signiﬁcantly reduced in the SCs of EAE
rats on the peak clinical day compared with healthy controls,
and that was reversed on recovery (Figure 1C). Importantly,
AMPK activity was remarkably increased in the SCs of EAE
rats treated with metformin compared with vehicle on
recovery (Figure 1C). These data imply that metformin
protects CNS integrity, thereby limiting clinical impairments
in EAE rats via AMPK-dependent mechanisms.
To further conﬁrm that metformin restores CNS integrity
and functions in EAE animals, we measured expressions of
the signatory genes of OL lineage cells and of neurotrophic
factors in the SCs of similarly treated EAE rats. As ex-
pected, levels of the mRNA transcripts of the signatory
genes of OPCs, ie, PDGF-aR and Olig2 (Figure 2, A and
B), and of OLs, ie, MBP and SOX10 (Figure 2, C and D),
were signiﬁcantly reduced, suggestive of OL loss in the SCs
of EAE rats treated with vehicle compared with healthy
controls, and were rescued by treatment with metformin.
Accordingly, levels of the mRNA transcripts of CNTF and
PDGF were reduced in the SCs of EAE rats treated with
vehicle compared with healthy controls and were abolished
by treatment with metformin (Figure 2, E and F). Consistent
with RNA data, the mean  SD CNTF protein level was
reduced signiﬁcantly (P < 0.001) in the SCs of EAE rats
treated with vehicle (812.8  80 pg/mg) compared with
healthy controls (1871.5  235.33 pg/mg) and was reversed
by treatment with metformin (1028.71  42.99 pg/mg).
These data provide evidence that metformin treatment
provides myelinogenic milieu for OLs and, thereby, restores
CNS integrity in EAE animals.
Next, to determine whether the observed protection of
CNS integrity and functions in EAE animals is ascribed to
the regulation of inﬂammatory response, we performed
gene expression proﬁling of inﬂammatory mediators. Levels
of the mRNA transcripts of the signatory genes of T cellsThe American Journal of Pathology - ajp.amjpathol.org(CD4 and CD8) and macrophages or microglia (Cd11b) were
elevated in the SCs of EAE rats treated with vehicle
compared with healthy controls and were attenuated by
treatment with metformin (Figure 3, A, C, and E). Compre-
hensive analysis using gene arrays further demonstrated that
the mRNA transcripts for proinﬂammatory cytokines that
participate in the activation, proliferation, and maturation of
T cells (CD4þ and CD8þ) and B cells and in the activation of
dendritic and CNS glial cells accompanied by TNF ligand
family cytokines were elevated in the SCs of EAE rats treated
with vehicle and were attenuated by treatment with metfor-
min (Table 2). In contrast, levels of the mRNA transcripts for
anti-inﬂammatory cytokines were reduced in the SCs of EAE
rats treated with vehicle and were rescued by treatment with
metformin (Table 2). Furthermore, levels of the mRNA
transcripts for CC and CXC family chemokines, including
CX3CL1, were elevated in the SCs of EAE rats treated with
vehicle and were attenuated by treatment with metformin
(Table 3). These chemokine expression data were validated
by measuring the levels of the mRNA transcripts of a few
chemokines, ie, CCL3, CCL5, and CXCL10, in the SCs of
treated EAE rats using real-time PCR analyses, and that
demonstrated the attenuation of their increased expressions in
the SCs of EAE rats by treatment with metformin (Figure 3,531
Table 2 Levels of Cytokine mRNA Transcripts (Arbitrary Units) in
the SCs of EAE Animals Treated with Vehicle or Metformin (Day 23
after Immunization)
Gene
EAE þ vehicle
vs control
EAE þ metformin
vs control
Anti-inﬂammatory cytokines
IL-1RA 1.57  0.02 2.56  0.3*
IL-10 <1.5 2.18  0.03*
Proinﬂammatory cytokines
IL-1a 1.65  0.81 <1.5
IL-1b 6.59  1.14 4.33  1.01**
IL-7 <1.5 1.51  0.34
IL-15 <1.5 1.65  0.3*
IL-17F <1.5 1.69  0.1*
IL-2 <1.5 1.73  0.14*
IL-16 <1.5 1.82  0.05*
IL-22 <1.5 1.95  0.01*
IL-9 <1.5 1.95  0.11*
IL-21 <1.5 2.04  0.1*
LIF <1.5 2.04  0.14*
Dendritic celleactivating cytokines
IL-12A <1.5 2.08  0.34*
IL-23A <1.5 2.39  0.04**
IL-12B <1.5 2.57  0.3**
TNF ligand family cytokines
TNF-a 3.42 1.54  0.14*
Tnfsf13b <1.5 2.04  0.04*
Tnfsf10 <1.5 2.18  0.04*
Tnfsf11 <1.5 2.23  0.11**
Tnfrsf11b <1.5 3.23  0.1**
Shown are the composite means  SEM of four to ﬁve samples analyzed
in each group.
*P < 0.05, **P < 0.01 versus EAE þ vehicle.
Figure 3 Metformin attenuates the expressions of inﬂammatory medi-
ators in the SCs of EAE rats. Induction of EAE in rats and treatment with
metformin or vehicle were as detailed in the legend to Figure 1. Composite
means  SEM of three to four samples per group analyzed in triplicate for
levels of CD4 (A), CCL3 (B), CD8 (C), CCL5 (D), CD11b (E), and CXCL10 (F)
mRNA transcripts in the SCs of EAE rats on day 23 after immunization. CON,
control. **P < 0.01, ***P < 0.001.
Paintlia et alB, D, and F). Together, these data suggest that metformin
attenuates autoimmunity in the CNS compartments of EAE
animals.
We earlier demonstrated that AICAR and metformin
attenuate EAE pathogenesis via attenuation of immune
responses and preservation of blood-brain barrier per-
meability.19e21 Therefore, we next determined to what
extent these protective effects of metformin in EAE are,
indeed, due to its local effects in the CNS compartment or to
effects on the immune response in the peripheral immune
system. To address this, spleens of similarly treated EAE
rats were analyzed for T-cell autoreactivity. The ratio of the
mRNA transcripts of the signatory genes of T helper (Th) 1
(IFN-g) and Th17 (IL-17A and ROR-gt) cells to CD4
mRNA transcripts were enhanced in the spleens of EAE rats
treated with vehicle compared with healthy controls and
were attenuated by treatment with metformin (Figure 4A).
In contrast, the ratio of the mRNA transcripts of the
signatory genes of Th2 (IL-4 and IL-10) and T regulatory
(FoxP3) cells to CD4 mRNA transcripts were reduced in the
spleens of EAE rats treated with vehicle compared with
healthy controls and were reversed by treatment with532metformin (Figure 4B). The ratio of theFoxP3 toCD4mRNA
transcripts was also enhanced in the spleens of healthy con-
trol rats treated with metformin compared with vehicle
(Figure 4B). These data suggest that metformin inhibits Th1
and Th17 cell phenotype responses and enhances the Th2
phenotype response and T regulatory cell generation in the
peripheral lymphoid organs of EAE animals.
Because the Th1 responses predominantly elicit IgG2a,
whereas Th2 responses produce higher levels of IgG1 in
mice,36 we next assessed whether metformin treatment in-
ﬂuences the pattern of isotypes of MBP-speciﬁc antibodies in
EAE rats. The elevated level of Ig isotype, IgG2a detected in
the sera of EAE rats treated with vehicle compared with
healthy controls was signiﬁcantly attenuated by treatment
with metformin (Figure 4C). Conversely, levels of Ig isotype,
IgG1 and IgG2b were signiﬁcantly increased in the sera of
EAE rats treated with metformin compared with vehicle
(Figure 4C). These data suggest that metformin treatment
biased the anti-MBP Ig response toward IgG1 and IgG2b and
against IgG2a, thereby supporting the Th1 to Th2 shift in the
blood of EAE animals.ajp.amjpathol.org - The American Journal of Pathology
Figure 4 Metformin attenuates T-cell autoreactivity in the peripheral
compartment of EAE rats. Induction of EAE in rats and treatment with
metformin or vehicle were as detailed in the legend to Figure 1. Composite
means  SEM of three to four samples per group analyzed in triplicate for
levels of IFN-g, IL-17A, and ROF-gt mRNA transcripts (A) and of IL-4, IL-10,
and FoxP3mRNA transcripts (B) to CD4mRNA transcripts ratio in the spleens
of EAE rats on day 23 after immunization. Composite means  SEM of three
to four samples per group analyzed in triplicate for levels of anti-MBP Ig, ie,
IgG2a, IgG1, and IgG2b (C), in the sera of EAE rats on day 23 after immu-
nization. AU, arbitrary units; CON, control; RLU, relative luminance units.
*P < 0.05, **P < 0.01, and ***P < 0.001.
Table 3 Levels of Chemokine mRNA Transcripts (Arbitrary Units)
in the SCs of EAE Animals Treated with Vehicle or Metformin (Day
23 after Immunization)
Gene EAE þ vehicle vs control EAE þ metformin vs control
CC family
CCL1 <1.5 2.08  0.3
CCL2 33.98  2.34 26.09  1.34*
CCL5 5.6  0.01 3.84  0.11*
CCL7 12.18  1.65 8.69  0.41**
CCL11 <1.5 2.95  0.04*
CCL17 2.17  0.01 1.5  0.1*
CCL19 <1.5 2.57  0.11*
CCL20 4.31  0.4 1.5  0.1**
CCL21 <1.5 1.99  0.1
CCL22 <1.5 1.99  0.1
CCL24 <1.5 1.54  0.0
CXC family
CXCL1 1.69  0.01 2.01  0.1*
CXCL3 <1.5 1.51  0.0
CXCL9 13.18  2.01 9.89  1.02**
CXCL10 5.3  0.21 3.87  0.014*
CXCL11 17.39  1.6 13.06  1.12*
CXCL12 <1.5 3.63  0.16**
CXCL13 2.5  0.14 1.79  0.32*
CXCL16 5.48  0.01 3.43  0.2*
CX3C family
CX3CL1 <1.5 4.57  1.02**
Shown are the composite means  SEM of four to ﬁve samples analyzed
in each group.
*P < 0.05, **P < 0.01 versus EAE þ Vehicle.
AMPK Signaling and OLs Survival in EAEMetformin Protects OLs in Activated Mixed Glial
Cultures Via AMPK Activation
The previously described ﬁndings demonstrated that met-
formin attenuates the inﬂammatory response in the peripheral
(blood and lymphoid organs) and CNS compartments to limit
clinical impairments in EAE animals.We earlier reported that
AMPK signaling attenuates the expression of inﬂammatory
mediators in astrocytes, microglia, and peritoneal micro-
phages stimulated with LPS in vitro.24 Consistently, AMPK
signaling has recently been documented to restrict IFN-ge
induced STAT-1 signaling, thereby inhibiting the activation
of astrocytes and microglia.22 To assess the underlying
mechanism behind OL protection, and, thus, the restoration
of CNS integrity and functions in metformin-treated EAE
animals, we treated 20% OPCeenriched mixed glial cultures
with metformin before stimulation with LPS and IFN-g for
different durations. As illustrated in Figure 5, AeD, LPS/
IFN-gestimulated mixed glial cultures had reduced OL
lineage cells, ie, O1þve and MBPþve OL populations, com-
pared with controls and were rescued by treatment with
metformin. These results were consistent with the observed
reduction in the levels of mRNA transcripts of the signatory
genes of OPCs (PDGF-aR) and OLs (MBP) in mixed glialThe American Journal of Pathology - ajp.amjpathol.orgcultures stimulated with LPS/IFN-g compared with controls
and were rescued by treatment with metformin (Figure 5, E
and F). These effects of metformin were reversed by
compound C (CC; AMPK inhibitor) and were mimicked by
treatment with AICAR (AMPK activator) in similarly acti-
vated mixed glial cultures (Figure 5, E and F). Note that the
cell death (20% to 25%) observed in mixed glial cultures
stimulated with LPS/IFN-g was also attenuated by treatment
with metformin or AICAR (data not shown). Together, these
data provide evidence that metformin protects OLs against
inﬂammatory insult in the CNS of EAE animals via AMPK
activation.533
Figure 5 Metformin protects OLs in activated
mixed glial cultures. Mixed glial cultures (2000/
cm2) enriched with OPCs were stimulated with 100
ng/mL of LPS and 100 ng/mL of recombinant IFN-g
protein in the presence or absence of 0.2 mmol/L
metformin. Shown are the composite means  SEM
of three to four samples analyzed in triplicate for
O1þve (A) and MBPþve (B) OL populations in mixed
glial cultures treated for 48 and 96 hours, respec-
tively. Representative ﬁelds of the slides (n Z 6)
depict O1þve (C) and MBPþve (D) OLs in treated
mixed glial cultures for 48 hours and 96 hours,
respectively. Slides were counterstained with
nuclear Hoechst dye. Shown are the composite
means  SEM of three or four samples analyzed in
triplicate for levels of PDGF-aR (E) and MBP (F)
mRNA transcripts in treated mixed glial cultures
for 96 hours. *P < 0.05, **P < 0.01, and ***P <
0.001.
Paintlia et alNext, to learn whether OL protection in activated mixed
glial cells treated with metformin is ascribed to the attenu-
ation of inﬂammatory response, we measured the expres-
sions of inﬂammatory mediators in similarly treated mixed
glial cultures. As illustrated in Figure 6,A and B, LPS/IFN-
gestimulated mixed glial cells had higher levels of the
mRNA transcripts of TNF-a and NOS-II compared with
controls and were attenuated by treatment with metformin.
Consistent with RNA data, TNF-a and NOS-II protein levels
were elevated in LPS/IFN-gestimulated mixed glial cells
comparedwith controls andwere attenuated by treatmentwith
metformin (Figure 6C). Accordingly, the byproduct of NOS-
II, NO (measured as nitrite) production, was elevated in the
culture supernatants of LPS/IFN-gestimulated mixed glial
cultures compared with controls and was attenuated by met-
formin (Figure 6D). Consistent with in vivo data (Figure 1C),
AMPK phosphorylation was enhanced in LPS/IFN-ge
stimulated mixed glial cells by treatment with metformin
(Figure 6C). This metformin-mediated attenuation of534inﬂammatory response in mixed glial cells stimulated with
LPS/IFN-g was abolished in the presence of CC (Figure 6).
These data imply that metformin inhibits the inﬂammatory
response in activated glial cells via AMPK activation.
Importantly, neurotrophic factors, ie, PDGF and CNTF,
expressed by glial cells are reported to play a signiﬁcant role
in the survival and development of OLs in the brain.37e40
Consistent with in vivo data (Figure 2, E and F), levels of
the mRNA transcripts of CNTF and PDGF were reduced in
mixed glial cells stimulated with LPS/IFN-g compared with
controls and were abolished by treatment with metformin
(Figure 7, A and B). In addition, metformin increased the
levels of the mRNA transcripts of CNTF and PDGF in
treated control mixed glial cells (Figure 7, A and B). These
effects of metformin in activated mixed glial cells were
reversed by CC (Figure 7, A and B). However, AICAR
mimicked the effect of metformin in activated mixed glial
cells (Figure 7, A and B). Consistent with RNA data,
mean  SD CNTF protein levels were reduced signiﬁcantlyajp.amjpathol.org - The American Journal of Pathology
Figure 6 Metformin attenuates the inﬂammatory response in activated
glial cells. Mixed glial cultures enriched with OPCs were stimulated with
LPS/IFN-g in the presence or absence of metformin as detailed in the
legend to Figure 5. Shown are the composite means  SEM of three to four
samples analyzed in triplicate for levels of TNF-a (A) and NOS-II (B) mRNA
transcripts in treated mixed glial cultures for 12 hours. The CC concentra-
tion was 5 mmol/L. C: Representative blot depicts the levels of TNF-a, NOS-
II, phospho-AMPK, and total AMPK (Tot-AMPK) protein in treated mixed
glial cultures for 24 hours. Shown are the composite means  SEM of three
or four samples analyzed in triplicate for nitrite level in the culture
supernatants of mixed glial cultures treated for 24 hours (D). *P < 0.05,
**P < 0.01, and ***P < 0.001.
AMPK Signaling and OLs Survival in EAE(P < 0.01) in the culture supernatants of mixed glial cultures
stimulated with LPS/IFN-g (10.43  1.12) compared with
controls (28.33  3.95) and were enhanced by treatment
with metformin (143  3.25). These results were consistent
with the observed reduced CNTF labeling in GFAPþve
astrocytes in mixed glial cultures stimulated with LPS/
IFN-g compared with controls, which was reversed by
metformin treatment (Figure 7C). These data suggest that
metformin provides myelinogenic milieu for OLs in acti-
vated mixed glial cultures via AMPK activation.
Metformin Protects OLs against Cytokine Toxicity
in Vitro and in Vivo
Th1 cytokines, including TNF-a, are reported to induce
oxidative stress in OLs that eventually leads to their apoptotic
cell death in in vitro conditions.41,42 We earlier documented
that TNF-a reduces cellular glutathione levels and increases
the generation of ceramide levels in OLs, which are
responsible for their apoptotic cell death.43 In addition, we
recently documented that TNF-ae and IL-17einduced
signaling mechanisms synergize to exacerbate the apoptotic
cell death of OLs.33 The present ﬁndings demonstrate
increased TNF-a expression in the SCs of EAE animals and
in activated mixed glial cells. Therefore, we next assessed
whether metformin protects OLs against cytokine toxicity in
EAE animals. To answer this question, puriﬁed OLs wereThe American Journal of Pathology - ajp.amjpathol.orgexposed to TNF-a plus IL-1b in the presence or absence of
metformin. The observed increased ROS generation in OLs
exposed to cytokines was attenuated by treatment with
metformin (Figure 8A). Because inﬂammatory cytokines are
known to deplete intracellular glutathione levels and even-
tually increase ROS generation and MDA (a byproduct of
membrane lipid peroxidation) production in cells,44,45 we
next measured the levels of MDA-containing proteins in
similarly treated OLs. Levels of MDA-containing proteins
were enhanced in OLs exposed to cytokines and were
reduced by treatment with metformin (Figure 8B). This effect
of metformin in OLs exposed to cytokines was abolished by
CC (Figure 8B). Accordingly, the SOD2 mRNA transcript
level was reduced in OLs exposed to cytokines compared
with controls and was reversed by treatment with metformin
(Figure 8C). Consistent with RNA data, SOD enzyme
activity was signiﬁcantly reduced in OLs exposed to cyto-
kines compared with controls and was reversed by treatment
with metformin (Figure 8D). In addition, a cytokine-
mediated increase in mitochondrial membrane depolariza-
tion in OLs exposed to cytokines compared with controls was
attenuated by treatment with metformin (Figure 8E).
Cytokine-induced AMPK activity in OLs compared with
controls was augmented by metformin in a dose-dependent
manner and was abolished by CC (Figure 7D). However,
AICAR-mediated induction of AMPK activation was not
enhanced in OLs exposed to cytokines (Figure 7D). Next, to
validate these ﬁndings in vivo, we analyzed the levels of
MDA-containing proteins in the SCs of EAE rats treated with
metformin or vehicle. The observed high levels of MDA-
containing proteins in the SCs of EAE rats treated with
vehicle on peak clinical day or recovery were attenuated by
treatment with metformin (Figure 9A). It was accompanied
by reduced levels of heme oxygenase-1 and SOD2 proteins in
the SCs of EAE rats treated with vehicle compared with
healthy controls on peak clinical day or recovery and was
abolished by treatment with metformin (Figure 9A). Like-
wise, SOD enzyme activity was reduced in the SCs of EAE
rats treated with vehicle compared with healthy controls on
peak clinical day or recovery and was abolished by treatment
with metformin (Figure 9B). Together, these data imply that
metformin-induced AMPK signaling attenuates oxidative
stress in OLs and enhances ROS detoxifying defenses in the
CNS of EAE animals.Discussion
The present study describes that AMPK signaling protects
OLs, and, thus, CNS integrity and functions, to limit clinical
impairments in the EAE model. The CNS has an inherent
capacity to generate myelin-forming OLs after episodes of
demyelination under pathologic conditions.5 Persistent CNS
demyelination is the characteristic entity for the MS brain
and SC trauma.6,7 Consistent with a previous report,19 met-
formin attenuated clinical impairments in EAE animals, and535
Figure 7 Metformin provides myelinogenic
milieu in activated mixed glial cultures. Mixed glial
cultures enriched with OPCs were stimulated with
LPS/IFN-g in the presence or absence of metformin
as detailed in the legend to Figure 5. A and B:
Composite means  SEM of three or four samples
analyzed in triplicate for levels of CNTF and PDGF
mRNA transcripts in treated mixed glial cultures for
12 hours. C: Representative ﬁelds of the slides
(n Z 4) depict the level of CNTF in GFAPþve
astrocytes in treated mixed glial cultures for 72
hours. Slides were counterstained with nuclear
Hoechst dye. Overlaying of images depicts the co-
localization of CNTF in GFAPþve astrocytes (right
panel). D: Shown are the composite means  SEM
of three or four samples analyzed in triplicate for
AMPK activity in OLs (2000/cm2) exposed to
cytokines (10 ng/mL of TNF-a plus 20 ng/mL of IL-
1b) and treated with metformin or other
compounds for 24 hours. The concentrations of CC
and AICAR used in the study were 5 mmol/L and
0.5 mmol/L, respectively. *P < 0.05, **P < 0.01,
and ***P < 0.001.
Paintlia et althese impairments were accompanied by the attenuation of
increased inﬂammation and demyelination in the CNS
compartment (Figure 1, A, B, and DeF). In addition,
expressions of the signatory genes of OL lineage cells and of
CNTF and PDGF, including AMPK activity, were enhanced
in the SCs of EAE animals treated with metformin
(Figures 1B and 2). Importantly, the increased T- and B-cell
autoreactivity and the activation of macrophages and resident
glial cells in the CNS of EAE animals were attenuated by
metformin as revealed by the gene expression proﬁling of
their signatory genes and of cytokines and chemokines
(Figure 3 and Tables 2 and 3). Accordingly, the observed
increased T-cell autoreactivity in the spleens of EAE animals
was attenuated by metformin, as revealed by the reduced536expressions of the signatory genes of Th1 and Th17 cells and
corresponding enhanced expressions of the signatory genes
of Th2 and T regulatory cells (Figure 4, A and B). Likewise,
metformin biased the elicited anti-MBP antibodies from
IgG2a to IgG1 and IgG2b in the blood of EAE animals,
thereby suggesting a Th1 to Th2 shift in the peripheral
immune system (Figure 4C). These in vivo ﬁndings were
supported by the reduction in OL lineage cells, ie, O1þve and
MBPþve OL populations and expressions of their signatory
genes in activated mixed glial cells and were rescued by
metformin or AICAR treatment (Figure 5). In addition,
expressions of the inﬂammatory mediators, ie, TNF-a and
NOS-II including NO production, were enhanced in mixed
glial cultures stimulated with LPS/IFN-g and were attenuatedajp.amjpathol.org - The American Journal of Pathology
Figure 8 Metformin attenuates oxidative
stress and protects mitochondria in OLs against
cytokine toxicity. OLs were exposed to cytokines as
detailed in the legend to Figure 7D. A: Composite
means  SEM of three to four samples analyzed in
triplicate for ROS level in treated OLs for 48 hours
using a CM-DCFDA assay kit. B: Representative blot
of three samples depicts the level of proteins
reacting to anti-MDA antibodies (Abs) in the total
lysate of OLs treated for 24 hours. C: Composite
means  SEM of three to four samples analyzed in
triplicate for SOD2 mRNA transcript level in treated
OLs for 12 hours. D: Composite means  SEM of
three to four samples analyzed in triplicate for SOD
activity in treated OLs for 24 hours. E: Represen-
tative ﬁelds of the slides (n Z 4) depict color
change in the mitochondrial membrane potential
from red to green as depolarization marker in OLs
for 24 hours analyzed by JC-1 staining. AU, arbi-
trary units; CON, control. *P < 0.05, **P < 0.01,
and ***P < 0.001.
AMPK Signaling and OLs Survival in EAEby metformin via AMPK activation (Figure 6). Consistent
with in vivo data, CNTF and PDGF expressions were also
reduced in the mixed glial cultures stimulated with LPS/IFN-
g and were abolished by metformin or AICAR treatment
(Figure 7, AeC). These effects of metformin in activated
mixed glial cells were reversed by CC (Figure 7, AeC).
Further studies demonstrated that the increased ROS gener-
ation and membrane lipid peroxidation in OLs exposed to
cytokines was attenuated by metformin (Figure 8, A and B).
It was accompanied by increased SOD2 expression and
its enzymatic activity, thereby protecting mitochondrial
health, including AMPK activity, in similarly treated OLs
(Figures 7D and 8, CeE). These effects of metformin on OLs
exposed to cytokines were reversed by CC (Figures 7D and 8,
AeC). Consistent with in vitro data, levels of MDA-
containing proteins were enhanced in the SCs of EAE
animals on peak clinical day or recovery and were reduced by
metformin treatment (Figure 9A). It was accompanied by
increased levels of ROS detoxifying enzymes, ie, heme
oxygenase-1 and SOD2, and of SOD enzyme activity in the
SCs of EAE animals treated with metformin compared with
vehicle (Figure 9). Altogether, these data provide evidence
that AMPK signaling is crucial to protect OLs and, thus, CNS
integrity and functions in EAE animals.The American Journal of Pathology - ajp.amjpathol.orgAMPK activity is tightly regulated by the cellular AMP/
ATP ratio that plays a central role in the regulation of
energy homeostasis and metabolic stress.46 Accumulating
evidence suggests that AMPK activation attenuates the
inﬂammatory response in different disease conditions and
the cytokine-induced inﬂammatory response in endothelial
cells via the inhibition of NF-kB activation.25,47,48 We
earlier documented that AMPK signaling attenuates the
inﬂammatory response in EAE mice and rats via T-cell
immunomodulation and the protection of blood-brain barrier
permeability.19e21 Because metformin is reported to cross
the blood-brain barrier,49 we observed that it attenuates the
expressions of cytokines that participate in the activation
and proliferation of Th1, Th17, and B cells and macro-
phages, including expressions of their signatory genes in the
SCs of EAE animals (Table 2 and Figure 3). In addition,
increased expressions of the chemokines that participate in
the inﬁltration of autoreactive T and B cells into the CNS
were attenuated by metformin in the SCs of EAE animals
(Table 3 and Figure 3). In agreement with a previous report
in EAE mice,19 T-cell autoreactivity was modulated in the
spleens of EAE rats by metformin that demonstrated Th1 to
Th2 biased with corresponding inhibition of Th17 cells and
generation of T regulatory cells (Figure 4, A and B). In537
Figure 9 Metformin attenuated oxidative stress with induction of ROS
detoxifying defense in the SCs of EAE rats. Induction of EAE in rats and
treatment with metformin or vehicle were as detailed in the legend to
Figure 1. A: Representative blots of three samples that depict the levels of
proteins reacting to anti-HO1, anti-SOD2, and anti-MDA antibodies (Abs) in
the SCs of EAE rats. B: Composite means  SEM of three to four samples
analyzed in triplicate for SOD activity in the SCs of EAE rats. CON, control;
MW, molecular weight; **P < 0.01.
Paintlia et aladdition, metformin biased the elicited anti-MBP antibodies
from IgG1 and IgG2b against IgG2a, thereby supporting the
Th1 to Th2 shift in the blood of EAE rats (Figure 4C). These
data suggest that metformin limits the expansion of T- and538B-cell autoreactivity in the peripheral and CNS compart-
ments of EAE animals via attenuation of the expressions of
cytokines and chemokines, ie, CC family (b-chemokine)
and CXC family (a-chemokine), in the CNS compartment.
In particular, a- and b-chemokines are reported to be critical
for MS/EAE pathogenesis that participates in the attraction
of autoreactive T and B cells, neutrophils, and dendritic
cells into the CNS.50e52 Consistently, metformin has
recently been documented to suppress endotoxin-induced
uveitis in Lewis rats via attenuation of inﬂammatory cyto-
kines and chemokines.53 Importantly, AMPK signaling is
reported to inhibit IFN-geinduced expression of TNF-a and
chemokines, ie, CCL2 and CXCL10, in astrocytes and
microglia.22 In addition, metformin-mediated induction of
AMPK signaling is reported to attenuate the inﬂammatory
response in vascular muscle cells.54 Consistently, we earlier
documented that AMPK attenuates LPS-induced inﬂam-
mation in the glial cells and in the brain via inhibition of
CCAAT/enhancer-binding protein transcription activity.24
Consistent with these observations, the observed LPS/IFN-
geinduced TNF-a and NOS-II expressions and NO
production in mixed glial cells were attenuated by metfor-
min via AMPK activation (Figure 6). These ﬁndings suggest
that metformin attenuates autoimmunity in the peripheral
(blood and lymphoid organs) and CNS compartments of
EAE animals via AMPK activation.
Neurotrophic factors, including CNTF, are known to
protect OLs against cytokine toxicity, which is reported to
enhance OPC differentiation to promote myelin repair in
various CNS demyelinating disorders.37,38 The trans-
plantation of CNTF-expressing OPCs has been reported to
promote remyelination and functional recovery in an SC
injury model.55 In addition, CNTF is reported to attenuate the
inﬂammatory response in EAE and optic neuritis models.56,57
We found that metformin increases the expressions of CNTF
and PDGF in activated mixed glial cultures (Figure 7, AeC)
and in the SCs of EAE animals (Figure 2, E and F). Accord-
ingly, OL lineage cell populations were increased in activated
mixed glial cultures (Figure 5, E and F) or in the SCs of EAE
animals treated with metformin (Figure 2, AeD). These
ﬁndings provide evidence that the immunomodulatory activ-
ities of AMPK signaling are accompanied by the induction of
neurotrophic factor expression in CNS cells (astrocytes) that
eventually providemyelinogenicmilieu forOLs to protectCNS
integrity. We recently documented that s-nitrosoglutathione
induces CNTF expression in astrocytes via a peroxisome pro-
liferatoreactivated receptor (PPAR)-gedependent mecha-
nism.32 PPAR activity is the important target of AMPK in
different cell types.58,59 Based on this information, we infer that
AMPK-induced PPAR activities may regulate the expressions
of neurotrophic factors in glial cells. However, these conclu-
sions warrant detailed investigation.
Proinﬂammatory cytokine signaling tends to affect OL
survival and can be antagonized by anti-inﬂammatory cyto-
kine-induced signaling mechanisms.10,12,13 In addition, we
earlier demonstrated that cytokine induces the apoptotic cellajp.amjpathol.org - The American Journal of Pathology
AMPK Signaling and OLs Survival in EAEdeath of OLs under CNS inﬂammatory disease condi-
tions.33,43 Metformin protected OLs against cytokine
toxicity via the attenuation of ROS generation and mito-
chondrial membrane depolarization (Figure 8). AMPK
signaling is reported to attenuate ROS generation in immune
and endothelial cells via the attenuation of NADPH oxidase
activity.60,61 In addition, endothelial cells lacking AMPK
are reported to exhibit aberrant NADPH oxidase expression
and ROS generation.62 AMPK signaling is reported to
induce PPAR-g co-activator-1a trans-activity via its direct
phosphorylation, which, in turn, suppresses ROS generation
with induction of ROS detoxifying defense in neurons under
pathologic conditions.63e65 Consistently, we observed
metformin-mediated increased expressions of ROS detoxi-
fying enzymes inOLs exposed to cytokines and in the SCs of
EAE animals. These ﬁndings provide evidence that AMPK
signaling protects OLs against cytokine toxicity via induc-
tion of ROS detoxifying defenses possibly via activation of
PGC-1a. Studies in this direction are currently under way in
our laboratory (Medical University of South Carolina,
Charleston, SC).
In conclusion, these ﬁndings provide unprecedented evi-
dence that AMPK signaling protects OLs to restore CNS
integrity and functions in EAE animals. These effects of
AMPK signaling were ascribed to the attenuation of auto-
immunity in the peripheral and CNS compartments that
eventually attenuates oxidative stress in OLs with increased
ROS detoxifying defenses in the CNS of EAE animals. These
ﬁndings suggest that AMPK activators, including metformin
as the ﬁrst-line choice of drug for type 2 diabetes mellitus,
have the potential to limit neurologic deﬁcits in MS and
related CNS disorders, including Alzheimer disease, stroke,
traumatic brain injury, and peripheral diabetic neuropathy.References
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